Want to see YARW full AI Analyst Report?
YARW Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
YARW Stock 12 Month Forecast
Average Price Target
$57.00
▲(51.19% Upside)
| Highest Price Target$58.00 | Average Price Target$57.00 | Lowest Price Target$56.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
LifeSci Capital
$56
Buy
48.54%
Upside
Initiated
08/04/26
Yarrow Therapeutics Initiated at Buy: Analyst Sees First-in-Class Graves’ and TED Therapy Driving ~$2.4B Peak Sales and Supports 12‑Month Upside TargetLifeSci Investment Abstract (Click full report link to access our full iniaon report) We are inia ng coverage on Yarrow Bioscience (Nasdaq: YARW) with an OUTPERFORM rang and a 12-month price target of $56/share. The Company’s lead asset, YB-101 (ex-China rights in-licensed from GenSci), is a potenally first-in-class thyroid-smula ng hormone receptor (TSHR) inhibitor, which has the potenal to address the underlying biology in both Eye Disease. Beyond its strong mechanisc raonale, YB-101 has already generated encouraging Phase I SAD data in Chinese paen ts with TED, demonstrang a favorable safety profile, rapid and dose-dependent effects on FT3 and FT4, sustained TSHR blockade, and clinically meaningful improvements in proptosis and overall response rate following a single dose.
BTIG
$58
Buy
53.85%
Upside
Initiated
08/03/26
TD Cowen
―
Buy
―
Initiated
07/27/26
H.C. Wainwright
―
Hold
―
Reiterated
12/17/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
LifeSci Capital
$56
Buy
48.54%
Upside
Initiated
08/04/26
Yarrow Therapeutics Initiated at Buy: Analyst Sees First-in-Class Graves’ and TED Therapy Driving ~$2.4B Peak Sales and Supports 12‑Month Upside TargetLifeSci Investment Abstract (Click full report link to access our full iniaon report) We are inia ng coverage on Yarrow Bioscience (Nasdaq: YARW) with an OUTPERFORM rang and a 12-month price target of $56/share. The Company’s lead asset, YB-101 (ex-China rights in-licensed from GenSci), is a potenally first-in-class thyroid-smula ng hormone receptor (TSHR) inhibitor, which has the potenal to address the underlying biology in both Eye Disease. Beyond its strong mechanisc raonale, YB-101 has already generated encouraging Phase I SAD data in Chinese paen ts with TED, demonstrang a favorable safety profile, rapid and dose-dependent effects on FT3 and FT4, sustained TSHR blockade, and clinically meaningful improvements in proptosis and overall response rate following a single dose.
BTIG
$58
Buy
53.85%
Upside
Initiated
08/03/26
TD Cowen
―
Buy
―
Initiated
07/27/26
H.C. Wainwright
―
Hold
―
Reiterated
12/17/25
Best Analysts Covering Yarrow Bioscience
3 Months
Success Rate
5/14 ratings generated profit
Average Return
-19.69%
Copying Rami Katkhuda's trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -19.69% per trade.
1 Year
Success Rate
1/14 ratings generated profit
Average Return
-65.62%
Copying Rami Katkhuda's trades and holding each position for 1 Year would result in 7.14% of your transactions generating a profit, with an average return of -65.62% per trade.
2 Years
Success Rate
0/14 ratings generated profit
Average Return
-80.63%
Copying Rami Katkhuda's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -80.63% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
YARW Analyst Recommendation Trends
Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
2
Buy
0
0
0
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
0
0
1
3
Each month's total comprises the sum of three months' worth of ratings.
YARW Financial Forecast
YARW Stock Forecast FAQ
What is YARW’s average 12-month price target, according to analysts?
Based on analyst ratings, Yarrow Bioscience’s 12-month average price target is 57.00.
What is YARW’s upside potential, based on the analysts’ average price target?
Yarrow Bioscience has 51.19% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is YARW a Buy, Sell or Hold?
Yarrow Bioscience has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Yarrow Bioscience’s price target?
The average price target for Yarrow Bioscience is 57.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $58.00 ,the lowest forecast is $56.00. The average price target represents 51.19% Increase from the current price of $37.7.
The highest analyst price target is $58.00 ,the lowest forecast is $56.00. The average price target represents 51.19% Increase from the current price of $37.7.
What do analysts say about Yarrow Bioscience?
Yarrow Bioscience’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of YARW?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.